Well, I tried.... basically what I expected.
Thank you for contacting Frequency Therapeutics, and we appreciate your interest in our company. Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Progenitor cells are the natural sources of tissues throughout your body and remain present through adulthood. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our therapies use proprietary combinations of small-molecule drugs to cause dormant progenitor cells to multiply and create new cells.
Please be aware that it is important that you not discuss your condition with anyone at our organization. We take very seriously the privacy of all individuals that may be participants in ongoing or future clinical trials that we sponsor, as we are legally bound by the rules as set forth in the 1996 HIPAA act. We encourage you to discuss your condition and your interest in trial participation with your healthcare providers, since your potential candidacy is based on their medical evaluation of your health status. Please appreciate that we are not able to discuss this matter with you any further based on the information we've provided herein.
Again, at this time we are unable to provide you with any additional details on the status of our programs. As Frequency Therapeutics is a privately held biotechnology company and not a medical provider, Federal Regulations prohibit the sharing of any information between our two parties. If you would like to stay informed about Frequency Therapeutics and any upcoming clinical trials evaluating our drug candidates, please refer to
www.clinicaltrials.gov. You may search by disease, location of clinical trials, or by the name of the company sponsoring the clinical trials. Additionally, you can reference the latest press releases available on our website
www.frequencytx.com for information regarding upcoming clinical trials. Thank you again for reaching out and we wish you well.
From:johnadams
Sent: Tuesday, August 21, 2018 1:12 PM
To: Info <info@frequencytx.com>
Subject: Tinnitus and fx322
Greetings,
Is there any way you can communicate with me any information regarding the affect that fx322 is having on test subjects' tinnitus?